Main Menu

Licensing and partnering opportunities

The Institute of Cancer Research currently has a number of partnering and licensing opportunities and any member of the Enterprise Unit would be pleased to review these with potential commercial collaborators. 

Abiraterone, a drug used to treat advanced prostate cancer was discovered and developed at the ICR

You can also download our Portfolio of Licensing and Partnering Opportunities (PDF)

The Faringdon Fund is a Proof of Concept Fund available to ICR faculty for the development of research ideas into commercial prospects – download more information about the Faringdon Fund (PDF) 

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.